Effects of antenatal betamethasone administration on fetal heart rate and behavior in twin pregnancy.
The efficacy of antenatal corticosteroid therapy in reducing the incidence of respiratory distress syndrome in twin pregnancy is controversial. The corticosteroid levels achieved with the current regimen might not be high enough to reach both siblings. In singleton fetuses, maternal betamethasone administration causes transient reductions in fetal heart rate (FHR), FHR variability, and body and breathing movements. We performed a prospective study to determine whether there are similar effects of betamethasone on FHR and behavior in preterm twin pregnancy and whether the effects occur similarly in both twin members. Eighteen women who were carrying twins received optimal corticosteroid treatment. Simultaneous recordings were made on twins before (day 0), during (days 1-2), and after (days 3-4) corticosteroid therapy using separate cardiotocography and ultrasound machines. Betamethasone administration was associated with significant transient decreases in basal FHR (day 1), FHR variability (days 2 and 3), and body and breathing movements (day 2). The overall changes in twins were similar to those previously found in singleton pregnancies. There was a high degree of association of response to betamethasone among individual members of twin pairs. The betamethasone-induced effects were unrelated to fetal sex, positioning, chorionicity, and discordance in size, but there was an effect of gestation on FHR. We conclude that the current regimen of antenatal corticosteroids used in preterm twin pregnancies results in observable physiologic and behavioral changes in twin pairs irrespective of their composition. This provides evidence that the achieved betamethasone levels are high enough to reach the compartment of either twin member.
Mulder
Eduard J H
EJ
Department of Perinatology and Gynecology, Wilhelmina Children's Hospital, Lundlaan 6, 3584 EA, Utrecht, The Netherlands. emulder@azu.nl
Derks
Jan B
JB
Visser
Gerard H A
GH
D000328:Adult; D001623:Betamethasone / Q000008:administration & dosage*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006340:Heart Rate, Fetal / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011446:Prospective Studies; D012127:Respiratory Distress Syndrome, Newborn / Q000517:prevention & control*; D015656:Respiratory Mechanics / Q000187:drug effects; D014427:Twins
D005938:Glucocorticoids; D001623:Betamethasone